Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer

O’Shaughnessy, J., Brufsky, A., Rugo, H. S., Tolaney, S. M., Punie, K., Sardesai, S., Hamilton, E., Loirat, D., Traina, T., Leon-Ferre, R., Hurvitz, S. A., Kalinsky, K., Bardia, A., Henry, S., Mayer, I., Zhu, Y., Phan, S., & Cortés, J. (2022). Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer. Breast Cancer Research and Treatment, 195(2), 127–139. https://doi.org/10.1007/s10549-022-06602-7

Authors:

Joyce O'Shaughnessy

Adam Brufsky

Hope S Rugo

Sara M Tolaney

Kevin Punie

Sagar Sardesai

Erika Hamilton

Delphine Loirat

Tiffany Traina

Roberto Leon-Ferre

Sara A Hurvitz